Mount Sinai Researchers Publish New Edition of Psychiatry "Bible"

In light of the accelerated pace of discovery in understanding psychiatric illnesses, experts from Mount Sinai have published the 4th edition of Neurobiology of Mental Illness.

New York, NY
 – August 7, 2013 /Press Release/  –– 

In light of the accelerated pace of discovery in understanding psychiatric illnesses, experts from the Icahn School of Medicine at Mount Sinai have published the fourth edition of Neurobiology of Mental Illness (Oxford University Press), a hallmark textbook in the field of psychiatry.

Edited by Dennis S. Charney, MD; Joseph D. Buxbaum, PhD; Pamela Sklar, MD, PhD; and Eric J. Nestler, MD, PhD, all of the Icahn School of Medicine at Mount Sinai, the text highlights new methodologies, diagnostic classifications, and clinical breakthroughs in psychiatric illness. With 32 new chapters, the text includes new highlights in psychiatric genomics, a groundbreaking field showing important promise in helping to address the neurobiological mechanisms behind mental illness. Released in parallel with the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), the textbook provides valuable perspective and insight on the changing landscape of psychiatric diagnosis and treatment.

“Psychiatry and Neuroscience are fields that are evolving at a rapid rate, with the emergence of psychiatric genomics, novel imaging techniques, and new drugs and drug targets resulting from these discoveries,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Icahn School of Medicine at Mount Sinai and Executive Vice President for Academic Affairs, The Mount Sinai Medical Center. “We hope that the essential updates we have made to this text will be valuable to psychiatry residents, psychiatric researchers, and doctoral students in the neurosciences and genetics.”

Dilip V. Jeste, MD, Distinguished Professor of Psychiatry and Neurosciences at the University of California at San Diego and 2012 President of the American Psychiatric Association, said, “As psychiatric diagnoses continue to be hotly debated, the Fourth Edition of this mainstay volume reminds the field of our deeper understanding of the neurobiological underpinnings of the brain, just a decade after the first Edition was published. This completely revamped Edition highlights articles by leaders in the fields of psychiatry and neurosciences and offers intelligent insights into how neuroscience may impact how we will diagnose and treat individuals suffering from mental illness in the very near future. The book continues to be a tour de force.”

Dennis Charney, MD, is a world expert in the neurobiology and treatment of mood and anxiety disorders. He has made fundamental contributions to the understanding of the causes of human anxiety, fear and depression and the discovery of new treatments for mood and anxiety disorders. More recently, his pioneering research has expanded to include the psychobiological mechanisms of human resilience to stress. Dr. Charney’s work in depression has led to new hypotheses regarding the mechanisms of antidepressant drugs and discovery of new and novel therapies for treatment-resistant depression including lithium and ketamine.  The work demonstrating that ketamine is a rapidly acting antidepressant has been hailed as one of the most exciting developments in antidepressant therapy in more than half a century. Dr. Charney is a member of the Institute of Medicine.

Joseph D. Buxbaum, PhD, is the G. Harold and Leila Y. Mathers Professor of Psychiatry, Genetics and Genomic Sciences, and Neuroscience, and the Director of the Seaver Autism Center at Mount Sinai. He has focused on understanding the molecular and genetic basis of autism spectrum conditions, which will allow for a better understanding of what causes them, leading to the development of novel therapeutics for these disorders. Dr. Buxbaum is a lead investigator in the Autism Genome Project. Dr. Buxbaum is the founder and co-leader of the Autism Sequencing Consortium, an international group of scientists studying the genome of thousands of autism patients, in order to accelerate our understanding of the causes and treatments of autism.

Pamela Sklar, MD, PhD, is Chief of the Division of Psychiatric Genomics, and Professor of Psychiatry, Neuroscience, Genetics and Genomic Sciences at Mount Sinai. Dr. Sklar is a neuroscientist, human geneticist, and clinical psychiatrist investigating the genetic causes of psychiatric disorders, including schizophrenia and bipolar disorder. A major focus of her work has been to identify susceptibility genes for psychiatric diseases by applying tools developed for understanding and characterizing human sequence variation. Dr. Sklar has long been involved in leadership positions for several consortia focusing on large-scale genomic studies including the International Schizophrenia Consortium and the Psychiatric Genomics Consortium.  

Eric J. Nestler, MD, PhD, is the Nash Family Professor and Chair of Neuroscience and Director of the Friedman Brain Institute at Mount Sinai. His laboratory studies the molecular and cellular changes that occur in regions of the brain important for reward, motivation, and emotions in response to chronic administration of a drug of abuse or chronic exposure to stress in animal models. The goal of Dr. Nestler’s research is to better understand the molecular mechanisms of addiction and depression based on work in animal models, and to use this information to develop improved treatments of these disorders. Dr. Nestler is a member of the Institute of Medicine and of the American Academy of Arts and Sciences.

To learn more about Neurobiology of Mental Illness, visit;jsessionid=1B0E3FC63C052F8422264E8C109A2ED6?cc=us〈=en&.

About The Mount Sinai Medical Center
The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Icahn School of Medicine at Mount Sinai. Established in 1968, the Icahn School of Medicine is one of the leading medical schools in the United States, with more than 3,400 faculty in 32 departments and 14 research institutes. It ranks among the top 20 medical schools both in National Institutes of Health (NIH) funding and by U.S. News & World Report. The Mount Sinai Hospital, founded in 1852, is a 1,171-bed tertiary- and quaternary-care teaching facility and one of the nation’s oldest, largest and most-respected voluntary hospitals. In 2012, U.S. News & World Report ranked The Mount Sinai Hospital 14th on its elite Honor Roll of the nation’s top hospitals based on reputation, safety, and other patient-care factors. 
For more information, visit 
Find Mount Sinai on:
Twitter @mountsinainyc
# # #